Engineered immune cells take aim at stubborn autoimmune disorder
Disease control
Not yet recruiting
This early-stage trial tests a new therapy called universal STAR-T cells in about 6 adults with autoimmune thrombocytopenia (low platelets) that hasn't responded to standard treatments. The cells are designed to target and calm the overactive immune system. The main goals are to …
Phase: PHASE1 • Sponsor: Jian Zhu • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC